First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC
“The increasing diversity of EGFR mutations has led to a growing number of therapeutic agents targeting various, narrowly defined subsets of EGFR mutation-positive lung cancer. When designing BH-30643, we pursued a different and broader ambition – a highly potent drug capable of inhibiting a wide spectrum of EGFR mutations, while sparing inhibition of wildtype EGFR and HER2, expected to provide a significant survival benefit and a better tolerated therapy for more patients,” said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics. “With this goal top of mind, we sought to break away from the entrenched thinking present in prior generations of EGFR inhibitor designs. With BH-30643, we seek to address the ongoing unmet medical need for this disease in a safe and effective manner, and we are committed to the rapid advancement of our OMNI-EGFRTM inhibitor in the clinic.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a